Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Identifieur interne : 001684 ( Main/Exploration ); précédent : 001683; suivant : 001685Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Auteurs : K. Papp [Canada] ; D. Thaçi [Allemagne] ; K. Reich [Allemagne] ; E. Riedl [Autriche] ; R G Langley [Canada] ; J G Krueger [États-Unis] ; A B Gottlieb [États-Unis] ; H. Nakagawa [Japon] ; E P Bowman [États-Unis] ; A. Mehta [États-Unis] ; Q. Li [États-Unis] ; Y. Zhou [États-Unis] ; R. Shames [États-Unis]Source :
- The British journal of dermatology [ 1365-2133 ] ; 2015.
Descripteurs français
- KwdFr :
- Administration par voie cutanée, Adolescent, Adulte, Adulte d'âge moyen, Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux (effets indésirables), Anticorps monoclonaux (pharmacocinétique), Anticorps monoclonaux humanisés (administration et posologie), Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (pharmacocinétique), Calendrier d'administration des médicaments, Femelle, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Produits dermatologiques (administration et posologie), Produits dermatologiques (effets indésirables), Produits dermatologiques (pharmacocinétique), Psoriasis (traitement médicamenteux), Résultat thérapeutique, Sous-unité p19 de l'interleukine-23 (immunologie), Sujet âgé, Sujet âgé de 80 ans ou plus.
- MESH :
- administration et posologie : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Produits dermatologiques.
- effets indésirables : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Produits dermatologiques.
- immunologie : Sous-unité p19 de l'interleukine-23.
- pharmacocinétique : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Produits dermatologiques.
- traitement médicamenteux : Psoriasis.
- Administration par voie cutanée, Adolescent, Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Femelle, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (pharmacokinetics), Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (pharmacokinetics), Dermatologic Agents (administration & dosage), Dermatologic Agents (adverse effects), Dermatologic Agents (pharmacokinetics), Double-Blind Method, Drug Administration Schedule, Female, Humans, Interleukin-23 Subunit p19 (immunology), Male, Middle Aged, Psoriasis (drug therapy), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents.
- chemical , adverse effects : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents.
- chemical , immunology : Interleukin-23 Subunit p19.
- chemical , pharmacokinetics : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Dermatologic Agents.
- drug therapy : Psoriasis.
- Administration, Cutaneous, Adolescent, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
Tildrakizumab is a high-affinity, humanized, IgG1/κ, anti-interleukin (IL)-23p19 monoclonal antibody that does not bind human IL-12 or p40 is being developed for the treatment of chronic plaque psoriasis.
DOI: 10.1111/bjd.13932
PubMed: 26042589
Affiliations:
- Allemagne, Autriche, Canada, Japon, États-Unis
- Hambourg, Massachusetts, New Jersey, Région de Kantō, Vienne (Autriche), État de New York
- Hambourg, Tokyo, Vienne (Autriche)
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E52
- to stream PubMed, to step Curation: 000E52
- to stream PubMed, to step Checkpoint: 000E52
- to stream Ncbi, to step Merge: 007458
- to stream Ncbi, to step Curation: 007458
- to stream Ncbi, to step Checkpoint: 007458
- to stream Main, to step Merge: 001686
- to stream Main, to step Curation: 001684
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.</title><author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name><affiliation wicri:level="1"><nlm:affiliation>Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4</wicri:regionArea><wicri:noRegion>N2J 1C4</wicri:noRegion></affiliation></author><author><name sortKey="Thaci, D" sort="Thaci, D" uniqKey="Thaci D" first="D" last="Thaçi">D. Thaçi</name><affiliation wicri:level="1"><nlm:affiliation>Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Reich, K" sort="Reich, K" uniqKey="Reich K" first="K" last="Reich">K. Reich</name><affiliation wicri:level="3"><nlm:affiliation>SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>SCIderm Research Institute and Dermatologikum Hamburg, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Riedl, E" sort="Riedl, E" uniqKey="Riedl E" first="E" last="Riedl">E. Riedl</name><affiliation wicri:level="3"><nlm:affiliation>Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R G" last="Langley">R G Langley</name><affiliation wicri:level="1"><nlm:affiliation>Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation></author><author><name sortKey="Krueger, J G" sort="Krueger, J G" uniqKey="Krueger J" first="J G" last="Krueger">J G Krueger</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Gottlieb, A B" sort="Gottlieb, A B" uniqKey="Gottlieb A" first="A B" last="Gottlieb">A B Gottlieb</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Tufts Medical Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Nakagawa, H" sort="Nakagawa, H" uniqKey="Nakagawa H" first="H" last="Nakagawa">H. Nakagawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Dermatology, The Jikei University School of Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Bowman, E P" sort="Bowman, E P" uniqKey="Bowman E" first="E P" last="Bowman">E P Bowman</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A" last="Mehta">A. Mehta</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Li, Q" sort="Li, Q" uniqKey="Li Q" first="Q" last="Li">Q. Li</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Zhou, Y" sort="Zhou, Y" uniqKey="Zhou Y" first="Y" last="Zhou">Y. Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Shames, R" sort="Shames, R" uniqKey="Shames R" first="R" last="Shames">R. Shames</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26042589</idno><idno type="pmid">26042589</idno><idno type="doi">10.1111/bjd.13932</idno><idno type="wicri:Area/PubMed/Corpus">000E52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E52</idno><idno type="wicri:Area/PubMed/Curation">000E52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E52</idno><idno type="wicri:Area/PubMed/Checkpoint">000E52</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E52</idno><idno type="wicri:Area/Ncbi/Merge">007458</idno><idno type="wicri:Area/Ncbi/Curation">007458</idno><idno type="wicri:Area/Ncbi/Checkpoint">007458</idno><idno type="wicri:Area/Main/Merge">001686</idno><idno type="wicri:Area/Main/Curation">001684</idno><idno type="wicri:Area/Main/Exploration">001684</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.</title><author><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name><affiliation wicri:level="1"><nlm:affiliation>Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Probity Medical Research, 135 Union Street East, Waterloo, ON, N2J 1C4</wicri:regionArea><wicri:noRegion>N2J 1C4</wicri:noRegion></affiliation></author><author><name sortKey="Thaci, D" sort="Thaci, D" uniqKey="Thaci D" first="D" last="Thaçi">D. Thaçi</name><affiliation wicri:level="1"><nlm:affiliation>Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck</wicri:regionArea><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion><wicri:noRegion>Lübeck</wicri:noRegion></affiliation></author><author><name sortKey="Reich, K" sort="Reich, K" uniqKey="Reich K" first="K" last="Reich">K. Reich</name><affiliation wicri:level="3"><nlm:affiliation>SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>SCIderm Research Institute and Dermatologikum Hamburg, Hamburg</wicri:regionArea><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName></affiliation></author><author><name sortKey="Riedl, E" sort="Riedl, E" uniqKey="Riedl E" first="E" last="Riedl">E. Riedl</name><affiliation wicri:level="3"><nlm:affiliation>Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R G" last="Langley">R G Langley</name><affiliation wicri:level="1"><nlm:affiliation>Dalhousie University, Halifax, NS, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Dalhousie University, Halifax, NS</wicri:regionArea><wicri:noRegion>NS</wicri:noRegion></affiliation></author><author><name sortKey="Krueger, J G" sort="Krueger, J G" uniqKey="Krueger J" first="J G" last="Krueger">J G Krueger</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Gottlieb, A B" sort="Gottlieb, A B" uniqKey="Gottlieb A" first="A B" last="Gottlieb">A B Gottlieb</name><affiliation wicri:level="2"><nlm:affiliation>Department of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Tufts Medical Center, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Nakagawa, H" sort="Nakagawa, H" uniqKey="Nakagawa H" first="H" last="Nakagawa">H. Nakagawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Dermatology, The Jikei University School of Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Bowman, E P" sort="Bowman, E P" uniqKey="Bowman E" first="E P" last="Bowman">E P Bowman</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A" last="Mehta">A. Mehta</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Li, Q" sort="Li, Q" uniqKey="Li Q" first="Q" last="Li">Q. Li</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Zhou, Y" sort="Zhou, Y" uniqKey="Zhou Y" first="Y" last="Zhou">Y. Zhou</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Shames, R" sort="Shames, R" uniqKey="Shames R" first="R" last="Shames">R. Shames</name><affiliation wicri:level="2"><nlm:affiliation>Merck & Co., Inc., Kenilworth, NJ, U.S.A.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Kenilworth, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><series><title level="j">The British journal of dermatology</title><idno type="eISSN">1365-2133</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (pharmacokinetics)</term><term>Dermatologic Agents (administration & dosage)</term><term>Dermatologic Agents (adverse effects)</term><term>Dermatologic Agents (pharmacokinetics)</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Interleukin-23 Subunit p19 (immunology)</term><term>Male</term><term>Middle Aged</term><term>Psoriasis (drug therapy)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie cutanée</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Anticorps monoclonaux (effets indésirables)</term><term>Anticorps monoclonaux (pharmacocinétique)</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (pharmacocinétique)</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Produits dermatologiques (administration et posologie)</term><term>Produits dermatologiques (effets indésirables)</term><term>Produits dermatologiques (pharmacocinétique)</term><term>Psoriasis (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Sous-unité p19 de l'interleukine-23 (immunologie)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Interleukin-23 Subunit p19</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Dermatologic Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Produits dermatologiques</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psoriasis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Produits dermatologiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-unité p19 de l'interleukine-23</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Produits dermatologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Psoriasis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie cutanée</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tildrakizumab is a high-affinity, humanized, IgG1/κ, anti-interleukin (IL)-23p19 monoclonal antibody that does not bind human IL-12 or p40 is being developed for the treatment of chronic plaque psoriasis.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li><li>Canada</li><li>Japon</li><li>États-Unis</li></country><region><li>Hambourg</li><li>Massachusetts</li><li>New Jersey</li><li>Région de Kantō</li><li>Vienne (Autriche)</li><li>État de New York</li></region><settlement><li>Hambourg</li><li>Tokyo</li><li>Vienne (Autriche)</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Papp, K" sort="Papp, K" uniqKey="Papp K" first="K" last="Papp">K. Papp</name></noRegion><name sortKey="Langley, R G" sort="Langley, R G" uniqKey="Langley R" first="R G" last="Langley">R G Langley</name></country><country name="Allemagne"><noRegion><name sortKey="Thaci, D" sort="Thaci, D" uniqKey="Thaci D" first="D" last="Thaçi">D. Thaçi</name></noRegion><name sortKey="Reich, K" sort="Reich, K" uniqKey="Reich K" first="K" last="Reich">K. Reich</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Riedl, E" sort="Riedl, E" uniqKey="Riedl E" first="E" last="Riedl">E. Riedl</name></region></country><country name="États-Unis"><region name="État de New York"><name sortKey="Krueger, J G" sort="Krueger, J G" uniqKey="Krueger J" first="J G" last="Krueger">J G Krueger</name></region><name sortKey="Bowman, E P" sort="Bowman, E P" uniqKey="Bowman E" first="E P" last="Bowman">E P Bowman</name><name sortKey="Gottlieb, A B" sort="Gottlieb, A B" uniqKey="Gottlieb A" first="A B" last="Gottlieb">A B Gottlieb</name><name sortKey="Li, Q" sort="Li, Q" uniqKey="Li Q" first="Q" last="Li">Q. Li</name><name sortKey="Mehta, A" sort="Mehta, A" uniqKey="Mehta A" first="A" last="Mehta">A. Mehta</name><name sortKey="Shames, R" sort="Shames, R" uniqKey="Shames R" first="R" last="Shames">R. Shames</name><name sortKey="Zhou, Y" sort="Zhou, Y" uniqKey="Zhou Y" first="Y" last="Zhou">Y. Zhou</name></country><country name="Japon"><region name="Région de Kantō"><name sortKey="Nakagawa, H" sort="Nakagawa, H" uniqKey="Nakagawa H" first="H" last="Nakagawa">H. Nakagawa</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001684 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001684 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26042589
|texte= Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26042589" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |